BB BIOTECH AG - Q3 2017 holdings

$3.61 Billion is the total value of BB BIOTECH AG's 27 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .

 Value Shares↓ Weighting
No holdings reported for quarter Q3 2017
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Biotech Focus N V #1
  • Biotech Invest N V #2
  • Biotech Target N V #3
  • Biotech Growth N V #4
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Celgene Corporation24Q1 201918.3%
Incyte Corporation24Q1 201915.3%
Gilead Sciences, Inc.24Q1 201914.2%
Vertex Pharmaceuticals Incorporated24Q1 20198.1%
Alexion Pharmaceuticals, Inc.24Q1 20195.7%
Halozyme Therapeutics, Inc.24Q1 20194.9%
Alnylam Pharmaceuticals, Inc.24Q1 20193.8%
Neurocrine Biosciences, Inc.23Q1 201910.3%
Regeneron Pharmaceuticals, Inc.22Q4 20183.5%
Achillion Pharmaceuticals, Inc.22Q3 20181.0%

View BB BIOTECH AG's complete holdings history.

Latest significant ownerships (13-D/G)

View BB BIOTECH AG's complete significant-ownership history.

Latest filings
TypeFiled
13F-NT2024-05-15
SC 13G2024-04-22
42024-04-04
13F-NT2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13

View BB BIOTECH AG's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (3612444000.0 != 3612448000.0)

Export BB BIOTECH AG's holdings